Skip to main content
Ilaria Iacobucci, PhD

Ilaria Iacobucci, PhD

  • Staff Scientist

Departments

Education

MSc (with honours) - Alma Mater Studiorum, University of Bologna, Bologna, Italy
PhD - Alma Mater Studiorum, University of Bologna, Bologna, Italy
Postdoctoral Fellowship - Alma Mater Studiorum, University of Bologna, Bologna, Italy
Assistant Professor - Department of Specialistic, Diagnostic and Experimental Medicine, University of Bologna, Bologna, Italy
Research Fellowship - St Jude Children’s Research Hospital, Memphis, TN

Research Interests

  • Genomic alterations underlying the pathogenesis of high-risk myeloid and lymphoid leukemia subtypes and development of faithful experimental models recapitulating human leukemia

Selected Publications

Iacobucci I, Wen J, Meggendorfer M, Choi JK, Shi L, Pounds SB, Carmichael C, Masih KE, Morris SM, Lindsley CR, Janke JL, Alexander TB, Song G, Qu C, Li Y, Payne-Turner D, Tomizawa D, Kiyokawa N, Valentine M, Valentine V, Basso G, Locatelli F, Enemark EJ, Kow Yin KS, Eng Juh AY, Ma X, Zhou X, Sioson E, Rusch M, Ries RE, Stieglitz E, Hunger SP, Wei A, To LB, Lewis ID, D'Andrea R, Kile BT, Brown AL, Scott HS, Hahn C, Marlton P, Pei D, Cheng C, Loh ML, Ebert EL, Meshinchi S, Haferlach T,  Mullighan CG. Genomic Subtyping and Therapeutic Targeting of Acute Erythroleukemia. Nat Genet Apr;51(4):694-704, 2019.

Baccarani M, Iacobucci I, Chiaretti S, Foà' R, Balasubramanian P, Paietta E, Foroni L, Jeromin S, Izzo B, Spinelli O, Varma N, Menif S, Terragna C, Seth T, Bidet A, Coriu D, Lunghi F, Mayer J, Scappini B, Langabeer S, Maier J, Burt E, Candoni A, Albano F, Luppi M, Zupan I, Lion T, Zadro R, di Raimondo F, Popak B, Rege-Cambrin G, Annunziata M, Ayala A, Salinas-Viedma V, Ines Prado A, Milner B, Galimberti S, Janssen J, Polli V, Comba L, Borsellino B, Annibali O, Crugnola M, Passamonti F. In Ph+BCR-ABL1P210+ acute lymphoblastic leukemia the e13a2 (B2A2) transcript is prevalent. Leukemia 2019.

Rampersaud E, Ziegler DS, Iacobucci I, Payne-Turner D, Churchman ML, Schrader KA, Joseph V, Offit K, Tucker K, Sutton R, Warby M, Chenevix-Trench G, Huntsman D, Tsoli M, Mead RS, Qu C, Leventaki V, Wu G, Mullighan CG. Germline deletion of ETV6 in familial acute lymphoblastic leukemia. Blood Adv Apr 9;3(7):1039-1046, 2019.

Gu Z, Churchman ML, Roberts KG, Moore I, Zhou X, Nakitandwe J, Hagiwara K, Pelletier S, Gingras S, Berns H, Payne-Turner D, Hill A, Iacobucci I, Shi L, Pounds S, Cheng C, Pei D, Qu C, Newman S, Devidas M, Dai Y, Reshmi SC, Gastier-Foster J, Raetz EA, Borowitz MJ, Wood BL, Carroll WL, Zweidler-McKay PA, Rabin KR, Mattano LA, Maloney KW, Rambaldi A, Spinelli O, Radich JP, Minden MD, Rowe JM, Luger S, Litzow MR, Tallman MS, Racevskis J, Zhang Y, Bhatia R, Kohlschmidt J, Mrózek K, Bloomfield CD, Stock W, Kornblau S, Kantarjian HM, Konopleva M, Evans WE, Jeha S, Pui CH, Yang J, Paietta E, Downing JR, Relling MV, Zhang J, Loh ML, Hunger SP, Mullighan CG. PAX5-driven subtypes of B-progenitor acute lymphoblastic leukemia. Nat Genet Jan 14, 2019.

Alexander TB*, Gu Z*, Iacobucci I* (co-first author), Dickerson K, Choi JK, Xu B, Payne-Turner D, Yoshihara H, Loh ML, Horan J, Buldini B, Basso G, Elitzur S, de Haas V, Zwaan CM, Yeoh A, Reinhardt D, Tomizawa D, Kiyokawa N, Lammens T, De Moerloose B, Catchpoole D, Hori H, Moorman A, Moore AS, Hrusak O, Meshinchi S, Orgel E, Devidas M, Borowitz M, Wood B, Heerema NA, Carrol A, Yang YL, Smith MA, Davidsen TM, Hermida LC, Gesuwan P, Marra MA, Ma Y, Mungall AJ, Moore RA, Jones SJM, Valentine M, Janke LJ, Rubnitz JE, Pui CH, Ding L, Liu Y, Zhang J, Nichols KE, Downing JR, Cao X, Shi L, Pounds S, Newman S, Pei D, Guidry Auvil JM, Gerhard DS, Hunger SP, Inaba H, Mullighan CG. The genetic basis and cell of origin of mixed phenotype acute leukaemia. Nature Oct;562(7727):373-379, 2018.

Simonetti G, Padella A, do Valle IF, Fontana MC, Fonzi E, Bruno S, Baldazzi C, Guadagnuolo V, Manfrini M, Ferrari A, Paolini S, Papayannidis C, Marconi G, Franchini E, Zuffa E, Laginestra MA, Zanotti F, Astolfi A, Iacobucci I, Bernardi S, Sazzini M, Ficarra E, Hernandez JM, Vandenberghe P, Cools J, Bullinger L, Ottaviani E, Testoni N, Cavo M, Haferlach T, Castellani G, Remondini D, Martinelli G. Aneuploid acute myeloid leukemia exhibits a signature of genomic alterations in the cell cycle and protein degradation machinery. Cancer Nov 27, 2018.

Ghelli Luserna Di Rorà A, Beeharry N, Imbrogno E, Ferrari A, Robustelli V, Righi S, Sabattini E, Verga Falzacappa MV, Ronchini C, Testoni N, Baldazzi C, Papayannidis C, Abbenante MC, Marconi G, Paolini S, Parisi S, Sartor C, Fontana MC, De Matteis S, Iacobucci I, Pelicci PG, Cavo M, Yen TJ, Martinelli G. Targeting WEE1 to enhance conventional therapies for acute lymphoblastic leukemia. J Hematol Oncol Aug 1;11(1):99, 2018.

Slayton WB, Schultz KR, Kairalla JA, Devidas M, Mi X, Pulsipher MA, Chang BH, Mullighan C, Iacobucci I, Silverman LB, Borowitz MJ, Carroll AJ, Heerema NA, Gastier-Foster JM, Wood BL, Mizrahy SL, Merchant T, Brown VI, Sieger L, Siegel MJ, Raetz EA, Winick NJ, Loh ML, Carroll WL, Hunger SP. Dasatinib Plus Intensive Chemotherapy in Children, Adolescents, and Young Adults With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Results of Children's Oncology Group Trial AALL0622. J Clin Oncol Aug 1;36(22):2306-2314, 2018.

Tzoneva G, Dieck CL, Oshima K, Ambesi-Impiombato A, Sánchez-Martín M, Madubata CJ, Khiabanian H, Yu J, Waanders E, Iacobucci I, Sulis ML, Kato M, Koh K, Paganin M, Basso G, Gastier-Foster JM, Loh ML, Kirschner-Schwabe R, Mullighan CG, Rabadan R, Ferrando AA. Clonal evolution mechanisms in NT5C2 mutant-relapsed acute lymphoblastic leukaemia. Nature Jan 25;553(7689):511-514, 2018.

Iacobucci I. Targeting precursor BCR in ALL. Blood Mar 2;129(9):1062-1064, 2017.

Iacobucci I, Mullighan CG. The genetic basis of acute lymphoblastic leukemia. Journal of Clinical Oncology Mar 20;35(9):975-983, 2017.

Di Rorà AG, Iacobucci I (co-corresponding author), Imbrogno E, Papayannidis C, Derenzini E, Ferrari A, Guadagnuolo V, Robustelli V, Parisi S, Sartor C, Abbenante MC, Paolini S, Martinelli G. Prexasertib, a Chk1/Chk2 inhibitor, increases the effectiveness of conventional therapy in B-/T- cell progenitor acute lymphoblastic leukemia. Oncotarget Aug 16;7(33):53377-53391, 2016.

Iacobucci I, Li Y, Roberts KG, Dobson SM, Kim JC, Payne-Turner D, Harvey RC, Valentine M, McCastlain K, Easton J, Yergeau D, Janke LJ, Shao Y, Chen I-ML, Rusch M, Zandi S, Kornblau SM, Konopleva M, Jabbour E, Paietta EM, Rowe JM, Pui C-H, Gastier-Foster J, Gu Z, Reshmi S, Loh M, Racevskis J, Tallman MS, Wiernik PH, Litzow MR, Willman CL, McPherson MS, Downing JR, Zhang J, Dick JE, Hunger SP, Mullighan CG. Truncating erythropoietin receptor rearrangements in acute lymphoblastic leukemia. Cancer Cell Feb 8;29(2):186-200, 2016.

Iacobucci I, Di Rorà AG, Falzacappa MV, Agostinelli C, Derenzini E, Ferrari A, Papayannidis C, Lonetti A, Righi S, Imbrogno E, Pomella S, Venturi C, Guadagnuolo V, Cattina F, Ottaviani E, Abbenante MC, Vitale A, Elia L, Russo D, Zinzani PL, Pileri S, Pelicci PG, Martinelli G. In vitro and in vivo single-agent efficacy of checkpoint kinase inhibition in acute lymphoblastic leukemia. J Hematol Oncol Nov 5;8:125, 2015.

Iacobucci I, Lonetti A, Venturi C, Ferrari A, Papayannidis C, Ottaviani E, Abbenante MC, Paolini S, Bresciani P, Potenza L, Parisi S., Cattina F, Soverini S, Russo D, Luppi M, and Martinelli G. Use of a high sensitive nanofluidic array for the detection of rare copies of BCR-ABL1 transcript in patients with Philadelphia-positive acute lymphoblastic leukemia in complete response. Leuk Res 38(5):581-5, 2014.

Iacobucci I, Lonetti A, Papayannidis C, Martinelli, G. Use of single nucleotide polymorphism array technology to improve the identification of chromosomal lesions in leukemia. Curr Cancer Drug Targets 13(7):791-810, 2013.

Iacobucci I, Lonetti A, Candoni A, Sazzini M, Papayannidis C, Formica S, Ottaviani E, Ferrari A, Michelutti A, Simeone E, Astolfi A, Abbenante MC, Parisi S, Cattina F, Malagola M, Russo D, Damiani D, Gherlinzoni F, Gottardi M, Baccarani M, Fanin R, Martinelli G. Profiling of drug-metabolizing enzymes/transporters in CD33+ acute myeloid leukemia patients treated with Gemtuzumab-Ozogamicin and Fludarabine, Cytarabine and Idarubicin. Pharmacogenomics J 13(4):335-41, 2013.

Iacobucci I, Papayannidis C, Lonetti A, Ferrari A, Baccarani M, Martinelli G. Cytogenetic and molecular predictors of outcome in acute lymphocytic leukemia: recent developments. Curr Hematol Malig Rep 7(2):133-43, 2012.

Iacobucci I, Iraci N, Messina M, Lonetti A, Chiaretti S, Valli E, Ferrari A, Papayannidis C, Paoloni F, Vitale A, Storlazzi CT, Ottaviani E, Guadagnuolo V, Durante S, Vignetti M, Soverini S, Pane F, Foa R, Baccarani M, Muschen M, Perini G, Martinelli G. IKAROS deletions dictate a unique gene expression signature in patients with adult B-cell acute lymphoblastic leukemia. PLoS One 7(7):e40934, 2012.

Iacobucci I, Ferrarini A, Sazzini M, Giacomelli E, Lonetti, A., Xumerle L, Ferrari A, Papayannidis C, Malerba G, Luiselli D, Boattini A, Garagnani P, Vitale A, Soverini S, Pane F, Baccarani M, Delledonne M, Martinelli G. Application of the whole-transcriptome shotgun sequencing approach to the study of Philadelphia-positive acute lymphoblastic leukemia. Blood Cancer J 2(3):e61, 2012.

Iacobucci I, Sazzini M, Garagnani P, Ferrari A, Boattini A, Lonetti A, Papayannidis C, Mantovani V, Marasco E, Ottaviani E, Soverini S, Girelli D, Luiselli D, Vignetti M, Baccarani M, Martinelli G. A polymorphism in the chromosome 9p21 ANRIL locus is associated to Philadelphia positive acute lymphoblastic leukemia. Leuk Res 35(8):1052-9, 2011.

Iacobucci I, Ferrari A, Lonetti A, Papayannidis C, Paoloni F, Trino S, Storlazzi CT, Ottaviani E, Cattina F, Impera L, Abbenante MC, Vignetti M, Vitale A, Potenza L, Paolini S, Soverini S, Pane F, Luppi M, Foa R, Baccarani M, Martinelli G. CDKN2A/B alterations impair prognosis in adult BCR-ABL1-positive acute lymphoblastic leukemia patients. Clin Cancer Res 17(23):7413-23, 2011.

Iacobucci I, Lonetti A, Paoloni F, Papayannidis C, Ferrari A, Storlazzi CT, Vignetti M, Cilloni D, Messa F, Guadagnuolo V, Paolini S, Elia L, Messina M, Vitale A, Meloni G, Soverini S, Pane F, Baccarani M, Foa R, Martinelli G. The PAX5 gene is frequently rearranged in BCR-ABL1-positive acute lymphoblastic leukemia but is not associated with outcome. A report on behalf of the GIMEMA Acute Leukemia Working Party. Haematologica 95(10):1683-90, 2010.

Iacobucci I, Lonetti A, Messa F, Ferrari A, Cilloni D, Soverini S, Paoloni F, Arruga F, Ottaviani E, Chiaretti S, Messina M, Vignetti M, Papayannidis C, Vitale A, Pane F, Piccaluga PP, Paolini S, Berton G, Baruzzi A,=., Ottaviani E, Soverini S, Astolfi A, Chiaretti S, Vitale A, Messa F, Impera L, Baldazzi C, D'Addabbo P, Papayannidis C, Lonoce A, Colarossi S, Vignetti M, Piccaluga PP, Paolini S, Russo D, Pane F, Saglio G, Baccarani M, Foa R, Martinelli G. Identification and molecular characterization of recurrent genomic deletions on 7p12 in the IKZF1 gene in a large cohort of BCR-ABL1-positive acute lymphoblastic leukemia patients: on behalf of Gruppo Italiano Malattie Ematologiche dell'Adulto Acute Leukemia Working Party (GIMEMA AL WP). Blood 114(10):2159-67, 2009.

Iacobucci I, Lonetti A, Messa F, Cilloni D, Arruga F, Ottaviani E, Paolini S, Papayannidis C, Piccaluga PP, Giannoulia P, Soverini S, Amabile M, Poerio A, Saglio G, Pane F, Berton G, Baruzzi, A, Vitale A, Chiaretti S, Perini G, Foa R, Baccarani M, Martinelli G. Expression of spliced oncogenic Ikaros isoforms in Philadelphia-positive acute lymphoblastic leukemia patients treated with tyrosine kinase inhibitors: implications for a new mechanism of resistance. Blood 112(9):3847-55, 2008.

Iacobucci I, Lonetti A, Cilloni D, Messa F, Ferrari A, Zuntini R, Ferrari S, Ottaviani E, Arruga F, Paolini S, Papayannidis C, Piccaluga PP, Soverini S, Saglio G, Pane F, Baruzzi A, Vignetti M, Berton G, Vitale A, Chiaretti S, Muschen M, Foa R, Baccarani M, Martinelli G. Identification of different Ikaros cDNA transcripts in Philadelphia-positive adult acute lymphoblastic leukemia by a high-throughput capillary electrophoresis sizing method. Haematologica 93(12):1814-21, 2008.

Palandri F*, Iacobucci I* (co-first author), Martinelli G, Amabile M, Poerio A, Testoni N, Soverini S, Castagnetti F, De Vivo A, Breccia M, Specchia G, Abruzzese E, Martino B, Cilloni D, Saglio G, Pane F, Liberati AM, Rosti G, Baccarani M, CML GWPo. Long-term outcome of complete cytogenetic responders after imatinib 400 mg in late chronic phase, philadelphia-positive chronic myeloid leukemia: the GIMEMA Working Party on CML. J Clin Oncol 26(1):106-11, 2008.

Iacobucci I, Galletti L, Amabile M, Soverini S, Baccarani M, Martinelli G, Monitoring BCR-ABL transcript levels by real-time quantitative polymerase chain reaction: a linear regression equation to convert from BCR-ABL/B2M ratio to estimated BCR-ABL/ABL ratio. Haematologica 92(3):429-30, 2007.

Iacobucci I, Saglio G, Rosti G, Testoni N, Pane F, Amabile M, Poerio A, Soverini S, Bassi S, Cilloni D, Bassan R, Breccia M, Lauria F, Izzo B, Merante S, Frassoni F, Paolini S, Montefusco E, Baccarani M, Martinelli G, Leukemia, GWPoCM. Achieving a major molecular response at the time of a complete cytogenetic response (CCgR) predicts a better duration of CCgR in imatinib-treated chronic myeloid leukemia patients. Clin Cancer Res 12(10):3037-42, 2006.

Iacobucci I, Rosti G, Amabile M, Poerio A, Soverini S, Cilloni D, Testoni N, Abruzzese E, Montefusco E, Ottaviani E, Iuliano F, Russo D, Gobbi M, Alimena G, Martino B, Terragna C, Pane F, Saglio G, Baccarani M, Martinelli G. Comparison between patients with Philadelphia-positive chronic phase chronic myeloid leukemia who obtained a complete cytogenetic response within 1 year of imatinib therapy and those who achieved such a response after 12 months of treatment. J Clin Oncol 24(3):454-9, 2006.

Last update: November 2019

Close